Medicaid Provider SpendingClaims paid 2018–2024 · HHS public file
Home › MA › Ayer › NPI 1477859254
Hospital

Nashoba Valley Medical Center, a Steward Family Hospital, INC

Nashoba Valley Medical Center, a Steward Family Hospital, INC was paid $10.90M by Medicaid between Jan 2018 and Aug 2024, across 165 billing codes. Its largest line is 99283, emergency room visit (moderate) — 15% of everything it billed.

33Billing provider infoNASHOBA VALLEY MEDICAL CENTER, A STEWARD FAMILY HOSPITAL, INC
AYER, MA 01432
33aNPI1477859254assigned 01/27/2011
33bProvider typeGeneral Acute Care Hospital
28Total paid$10.90M
24GClaims240,726
24DCodes billed165
24AFirst – last monthJan 2018 – Aug 2024
Compared with peers

Next to other General Acute Care Hospital providers in Massachusetts

Rank by total paid#42 of 66
Median peer was paid$29.11M
This provider vs. median0.4×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

$0$100K$200K2018201920202021202220232024
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
YearClaimsPaid
201838,315$1.69M
201938,562$1.55M
202029,492$1.26M
202136,668$1.78M
202243,131$2.00M
202334,698$1.71M
2024incomplete19,860$913K
Box 24 · Service lines

What it billed for

CodeServiceShareClaimsBene. recordsPaid
99283 Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity 15% 11,027 10,358 $1.68M
99285 Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life 12% 7,959 7,182 $1.26M
99284 Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity 9.7% 7,062 6,627 $1.06M
97110 Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion 9.7% 15,290 4,242 $1.05M
96361 Intravenous infusion, hydration; each additional hour 9.2% 3,084 2,684 $1.01M
43239 Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple 9.2% 1,293 1,245 $1.00M
99214 Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity 4.0% 2,762 2,535 $440K
99211 Office or other outpatient visit for the evaluation and management of an established patient, minimal severity 2.4% 1,845 1,753 $260K
G0463 Hospital outpatient clinic visit for assessment and management of a patient 2.0% 7,473 6,832 $221K
74177 Computed tomography, abdomen and pelvis; with contrast material 1.9% 1,513 1,442 $210K
U0003 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r 1.9% 3,963 3,493 $205K
99282 Emergency department visit for the evaluation and management, low to moderate severity 1.7% 1,465 1,415 $185K
153 more codes
70450 Computed tomography, head or brain; without contrast material 1.6% 1,615 $172K
77063 Screening digital breast tomosynthesis, bilateral 1.4% 1,912 $156K
96365 Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour 1.4% 1,267 $155K
45380 Colonoscopy, flexible; with biopsy, single or multiple 1.3% 158 $136K
97162 1.2% 1,732 $130K
97140 Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) <1% 3,981 $86K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay <1% 2,071 $69K
U0005 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 <1% 3,898 $68K
85025 Blood count; complete (CBC), automated, and automated differential WBC count <1% 15,274 $66K
87502 Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets <1% 1,155 $60K
87635 Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe <1% 1,299 $60K
87426 Infectious agent antigen detection, SARS-CoV-2 (COVID-19) <1% 2,497 $59K
71046 Radiologic examination, chest; 2 views <1% 4,326 $54K
45378 Colonoscopy, flexible; diagnostic, including collection of specimen(s) <1% 35 $51K
77067 Screening mammography, bilateral, including computer-aided detection <1% 2,018 $46K
ATP14 <1% 5,474 $41K
93306 Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete <1% 196 $41K
99213 Doctor's office visit, returning patient (routine) <1% 283 $39K
94640 Pressurized or nonpressurized inhalation treatment for acute airway obstruction <1% 478 $38K
74176 Computed tomography, abdomen and pelvis; without contrast material <1% 356 $37K
76856 Ultrasound, pelvic (nonobstetric), real time with image documentation; complete <1% 346 $35K
96374 Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance <1% 5,374 $32K
87624 Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types <1% 1,155 $31K
97113 <1% 645 $30K
96375 Therapeutic injection; each additional sequential IV push <1% 3,635 $29K
96360 Intravenous infusion, hydration; initial, 31 minutes to 1 hour <1% 225 $29K
80053 Comprehensive metabolic panel <1% 11,881 $27K
76830 Ultrasound, transvaginal <1% 279 $26K
93017 <1% 251 $25K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed <1% 917 $20K
84484 <1% 4,041 $19K
93005 Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report <1% 5,667 $18K
ATP08 <1% 2,967 $18K
64493 <1% 30 $17K
93971 <1% 14 $16K
84443 Thyroid stimulating hormone (TSH) <1% 2,277 $16K
95886 <1% 76 $15K
88142 <1% 905 $15K
87086 Culture, bacterial; quantitative colony count, urine <1% 3,299 $15K
U0004 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r <1% 250 $15K
87804 Infectious agent antigen detection by immunoassay; Influenza, each type <1% 1,531 $13K
76705 Ultrasound, abdominal, real time with image documentation; limited <1% 129 $13K
82306 Vitamin D; 25 hydroxy, includes fraction(s), if performed <1% 793 $13K
80048 Basic metabolic panel (calcium, ionized) <1% 6,783 $12K
76536 <1% 95 $11K
78452 Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress <1% 39 $10K
20553 <1% 83 $10K
99281 Emergency department visit for the evaluation and management, self-limited or minor <1% 69 $10K
83690 <1% 2,084 $9K
83036 Hemoglobin; glycosylated (A1C) <1% 2,148 $8K
81001 <1% 4,717 $8K
87651 Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe <1% 310 $8K
87591 Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe <1% 299 $7K
87491 Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe <1% 299 $7K
97803 <1% 124 $7K
20610 <1% 46 $7K
83735 <1% 2,030 $7K
84600 <1% 614 $7K
G0378 Hospital observation service, per hour <1% 515 $7K
73562 <1% 269 $7K
81025 <1% 1,240 $6K
87632 <1% 43 $6K
77080 <1% 116 $6K
80050 General health panel <1% 319 $5K
85027 <1% 1,684 $5K
87633 Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets <1% 12 $5K
G0108 Diabetes outpatient self-management training services, individual, per 30 minutes <1% 71 $4K
73630 <1% 187 $4K
88305 Level IV - Surgical pathology, gross and microscopic examination <1% 1,316 $4K
J7120 Ringers lactate infusion, up to 1000 cc <1% 682 $3K
36415 Collection of venous blood by venipuncture <1% 12,127 $3K
J2704 Injection, propofol, 10 mg <1% 4,156 $3K
ATP17 <1% 581 $3K
76642 <1% 53 $3K
71250 <1% 57 $3K
84703 <1% 533 $3K
J2405 Injection, ondansetron hydrochloride, per 1 mg <1% 3,311 $3K
87798 Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism <1% 88 $3K
96372 Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular <1% 1,162 $3K
85610 <1% 1,615 $3K
83880 <1% 243 $3K
J3010 Injection, fentanyl citrate, 0.1 mg <1% 2,070 $3K
87186 <1% 531 $3K
73030 <1% 88 $2K
84439 <1% 444 $2K
87077 <1% 484 $2K
64494 <1% 34 $2K
73610 <1% 70 $2K
81003 <1% 1,552 $2K
J1885 Injection, ketorolac tromethamine, per 15 mg <1% 3,157 $2K
85379 <1% 267 $2K
J2250 Injection, midazolam hydrochloride, per 1 mg <1% 411 $1K
J1030 Injection, methylprednisolone acetate, 40 mg <1% 2,661 $1K
J1100 Injection, dexamethasone sodium phosphate, 1 mg <1% 736 $1K
99291 Critical care, evaluation and management of the critically ill patient, first 30-74 minutes <1% 16 $1K
77065 Tomosynthesis, mammo <1% 29 $1K
82728 <1% 167 $1K
ATP15 <1% 195 $1K
82607 <1% 133 $1K
73502 <1% 41 $877.69
J7030 Infusion, normal saline solution , 1000 cc <1% 3,210 $863.56
ATP03 <1% 232 $836.46
J3490 Unclassified drugs <1% 19 $833.16
83540 <1% 198 $727.52
J1200 Injection, diphenhydramine hcl, up to 50 mg <1% 107 $723.41
83605 <1% 123 $667.05
87486 <1% 26 $640.20
82947 <1% 1,191 $626.32
82570 <1% 198 $496.00
85652 <1% 345 $493.48
J1170 Injection, hydromorphone, up to 4 mg <1% 136 $454.64
90715 <1% 12 $413.58
G0123 Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision <1% 850 $351.00
J2060 Injection, lorazepam, 2 mg <1% 188 $336.96
84466 <1% 42 $323.01
73130 <1% 12 $315.32
87880 Infectious agent antigen detection by immunoassay; Streptococcus, group A <1% 37 $295.73
87807 <1% 25 $219.45
88175 Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer <1% 12 $211.23
J2001 Injection, lidocaine hcl for intravenous infusion, 10 mg <1% 2,522 $206.75
71045 Radiologic examination, chest; single view <1% 803 $201.88
86140 <1% 58 $189.28
80061 Lipid panel <1% 2,031 $178.98
Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml <1% 1,307 $171.56
J2270 Injection, morphine sulfate, up to 10 mg <1% 266 $168.91
87040 <1% 21 $138.45
85730 <1% 41 $122.00
87081 <1% 25 $115.12
83550 <1% 16 $72.16
87070 <1% 14 $71.04
88342 <1% 432 $56.76
87088 <1% 14 $51.66
85651 <1% 20 $43.80
90471 Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine <1% 13 $40.10
85007 <1% 13 $21.91
82043 <1% 12 $21.12
84100 <1% 116 $8.50
83615 <1% 15 $5.50
J7512 Prednisone, immediate release or delayed release, oral, 1 mg <1% 45 $0.38
80076 0% 539 $0.00
A9502 Technetium tc-99m tetrofosmin, diagnostic, per study dose 0% 26 $0.00
94060 0% 12 $0.00
88313 0% 40 $0.00
94729 0% 12 $0.00
J1010 Injection, methylprednisolone acetate, 1 mg 0% 27 $0.00
96376 0% 193 $0.00
A9500 Technetium tc-99m sestamibi, diagnostic, per study dose 0% 12 $0.00
80320 0% 28 $0.00
A9579 Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml 0% 38 $0.00
U0002 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc 0% 280 $0.00
J0690 Injection, cefazolin sodium, 500 mg 0% 32 $0.00
0241U Neonatal screening for hereditary disorders, genomic sequence analysis panel 0% 69 $0.00
J0696 Injection, ceftriaxone sodium, per 250 mg 0% 17 $0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialRICH, MARK (EVP/CFO)
Parent organizationSTEWARD HEALTH CARE SYSTEM LLC
Same official

Other billing entities under RICH, MARK

Full network →
ProviderLocationPaid
Steward ST. Elizabeth's Medical Center of Boston, INC.Boston, MA$2.16M
Steward ST. Elizabeth's Medical Center of Boston, INC.Boston, MA$881K
SHC Youngstown Ohio Outpatient Services LLCAustintown, OH$481K
Nashoba Valley Medical Center, a Steward Family Hospital, INC.Ayer, MA$239K
Steward Norwood Hospital, INC.Norwood, MA$45K
Steward Good Samaritan Radiation Oncology Center, INC.Brockton, MA$130.15

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.